Novel Anti-CD20/BCMA Bispecific Autologous CAR-T Therapy targeting LN and SLE ROCKVILLE, Md., Nov. 16, 2024 /PRNewswire/ — AbelZeta Pharma, Inc. (“AbelZeta” or the “Company”), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.